Objective     To investigate the therapeutic mechanism of dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin on inflammatory bowel disease (IBD) by observing its effects on serum IL-8

TNF-α and GLP-2 levels as well as colonic myeloperoxidase (MPO) activity in mice with ulcerative colitis induced by trinitrobenzenesulfonic acid (TNBS).      Methods     Totally 48 male BALB/c mice were equally divided into 6 groups: a normal control group

a model group of IBD

a positive control group with sulfasalazine (520 mg/kg)

and 3 therapeutic groups with high

medium and low alogliptin doses (1

0.3 and 0.1 mg/kg

respectively). The mice in the model group were treated by rectal instillation with TNBS to establish IBD models and given drugs through intragastric administration to observe the effects of alogliptin on diarrhea

colonic mucosa lesion and colonic MPO activity

as well as serum IL-8

TNF-a and GLP-2 levels in the mice with ulcerative colitis.      Results     Compared with those of the model group

the clinical symptoms and lesion of colonic mucosa in the therapeutic groups with high and medium alogliptin doses were remarkably improved. In the two groups

the DAI score (P0.01)

colonic MPO activity (P0.05) and serum IL-8 and TNF-α levels (P0.05) decreased significantly. The serum GLP-2 level

however

increased significantly (P0.05) as compared with that of the normal control group or the model group.      Conclusion     DPP-4 inhibitor alogliptin can effectively inhibit the infiltration of colonic inflammatory cells and alleviate the pathological damage of colonic mucosa

and thus has a significant therapeutic effect on mice with ulcerative colitis induced by TNBS.